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How Harmful is Conventional Right 
Ventricular Apical Pacing?
Iatrogenic Left Bundle Branch Block: 
Need for Alternate Site Pacing
Kostas G. Kappos, MD, Vassiliki Tsagou, MD, Antonis S. Manolis, MD
A B S T R A C T
The right ventricular (RV) apex has been used as the traditional pacing site since 
the development of transvenous pacing in 1959. Some studies suggest that pacing the 
RV apex may cause an “iatrogenic” left bundle branch block and remodeling of the 
left ventricle and is therefore harmful. In the past decade, the need for alternate site 
pacing became imperative and there have been a multitude of studies of the hemody-
namic, electrophysiological, electrocardiographic, and clinical effects of ventricular 
pacing at other sites. Pacing of the left ventricle singly or with biventricular pacing 
has emerged as an effective and safe therapy for moderate to severe congestive heart 
failure in patients with prolonged QRS complexes. Studies of alternate RV sites, like 
the RV outflow tract, have given mixed results, and further clarification of the specific 
sites of the RV outflow tract is needed. Direct His-bundle pacing is an attractive alter-
nate pacing site because of the possible hemodynamic benefits that could be obtained 
by a normal activation sequence, but the small size and anatomic position of the His 
bundle have made this approach difficult. Bifocal RV resynchronization therapies 
have been used as an alternative to biventricular pacing.
I N T R O D U C T I O N
Since the first report of the use of the transvenous route for pacemaker implanta-
tion in 1959 by Furman, the right ventricular (RV) apical region has represented the 
preferred pacing site [1]. The main reason has been the ease of implantation and the 
stability of passive-fixation leads in the apical trabeculae. However, apart from some 
specific diseases like hypertrophic cardiomyopathy, RV apical pacing often results 
in substantial functional, hemodynamic, electrical, and structural changes as already 
demonstrated in many studies. It is interesting to note that the roentgenogram from the 
early report of Furman shows the pacing lead position in the RV outflow tract (RVOT) 
[1]. As early as 1925, Carl Wiggers showed that RV apical pacing was associated with 
a diminished dP/dt and an asynchronous contraction pattern [2]. It is only in recent 
years that interest in the use of alternate pacing sites has developed.
Tse et al [3] have shown that RV apical pacing produces significant myocardial 
perfusion defects, apical wall-motion abnormalities (incidence increases with the du-
ration of pacing), and worsening of global left ventricular function during long-term 
pacing. Several other studies confirmed the hypothesis that RV apical pacing negatively 
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affects systolic and diastolic function [4-7] Permanent RV api-
cal pacing was also shown to induce abnormal histological 
changes, asymmetrical hypertrophy, and thinning of the left 
ventricle [8,9]. The adverse effect of RV apical pacing on car-
diac function was demonstrated in patients with normal6 and 
reduced left ventricular ejection fraction [10]. Such findings 
are important because they strongly suggest that RV apical 
pacing may promote progression of heart failure (HF) in 
patients with left ventricular dysfunction.
The distance of the pacing site in the RV from the His-
Purkinje system causes a prolongation of the QRS complex [11] 
and substantial changes of the activation pattern compared 
with the normal physiological status [12]. In 1925, Wiggers [2] 
proposed that with longer distances from the artificial pacing 
site to the His-Purkinje system the resulting beats would be 
weaker. Experimental animal studies demonstrated a negative 
linear correlation between acute hemodynamic changes and 
ventricular activation time expressed as the QRS width during 
pacing at different pacing sites [13,14]. Based on these data, 
it may be expected that pacing in or near the His-Purkinje 
system will lead to faster and more homogenous ventricular 
activation with a corresponding reduction in QRS duration 
and a more favourable hemodynamic response.
S P O N T A N E O U S  L E F T  B U N D L E  B R A N C H  
B L O C K  ( L B B B )
Approximately 15% of all heart failure patients have an 
inter- or intra-ventricular conduction delay (QRS >120 ms) 
[15,16]. Over 30% of moderate to severe HF patients have a 
prolonged QRS. The prevalence of conduction defects increas-
es with severity of HF [17-19]. Shenkman and colleagues [16] 
found the factors associated with prolonged QRS to include 
older age, male gender, Caucasian race, lower ejection fraction 
(EF), and higher left ventricular end diastolic diameter. About 
a third of patients with systolic HF show widening of the QRS 
complex on the surface electrocardiogram (ECG) usually in 
combination with left bundle branch block (LBBB).
Masoudi and colleagues [20] used retrospective medical 
chart data of 19,710 pts Medicare beneficiaries hospitalized 
for HF and in whom left ventricular systolic function was 
confirmed. LBBB was present in 8% of those with preserved 
left ventricular systolic function (diastolic HF) and in 24% 
of those with EF <50% (p<0.001). Aaronson [18] developed 
and validated a multivariable survival model for ambula-
tory advanced HF patients wait-listed for a heart transplant. 
Intraventricular conduction delay (IVCD) (QRS >120 ms) 
was present in 27% of the 268 patients in derivation sample, 
and in 53% of the 199 patients in validation sample. IVCD 
was identified as contributing risk factor. Other studies have 
shown that of the entire HF population about 15% have a 
wide QRS. LBBB affects prognosis in patients with HF and 
is also associated with increased overall mortality and higher 
risk of sudden death [21]. Interventricular conduction distur-
bances are common in HF patients, mainly as QRS >150 ms 
(mean 27%), while worsening of HF is associated with QRS 
complex widening. Increased 1-year mortality with presence 
of complete LBBB (QRS >140 ms) has been shown [22]. Risk 
remains significant even after adjusting for age, underlying 
cardiac disease, indicators of HF severity, and HF medica-
tions. The VEST Study [23] demonstrated that QRS dura-
tion was found to be an independent predictor of mortality. 
Patients with wider QRS (>200 ms) had five times greater 
mortality risk than those with the narrowest (<90 ms). Rest-
ing ECG is a powerful, sensitive, accessible and inexpensive 
marker of prognosis in patients with dilated cardiomyopathy 
and congestive HF. The presence of LBBB creates functional 
abnormalities in HF patients [25], increases isovolumic con-
traction, increases relaxation time, and diminishes the filling 
time. Atrioventricular (AV) conduction disturbances are also 
common in HF patients, mainly as PR interval prolongation 
(>200 ms), in up to 60% in this population [24].
The last few years, new terms have been introduced: 
Ventricular dyssynchrony is defined as the effect caused 
by intra- and inter-ventricular conduction defects or bundle 
branch block. What we know about the causes of ventricular 
dyssynchrony [26] is that inter- or intra-ventricular conduction 
delays usually manifest as LBBB, regional wall motion abnor-
malities are associated with increased workload and stress 
compromising ventricular mechanics and disruption of myo-
cardial collagen matrix impairing electrical conduction and 
mechanical efficiency. It is estimated that approximately 20% 
of all HF patients may have ventricular dyssynchrony [27].
Cardiac resynchronization therapy (CRT) is defined as 
the therapeutic intent of atrial synchronized biventricular pac-
ing for patients with HF and ventricular dyssynchrony. The aim 
of this therapy is to resynchronize the ventricular activation 
sequence, and to better coordinate atrio-ventricular (AV) tim-
ing to improve pumping efficiency. Cardiac resynchronization 
therapy is currently indicated for the reduction of symptoms of 
moderate to severe HF (New York Heart Association-NYHA 
functional class III or IV) in those patients who remain symp-
tomatic despite stable, optimal medical therapy, and have a left 
ventricular ejection fraction (EF) ≤35% and a QRS duration 
≥130 ms. An implantable cardioverter defibrillator (ICD) is 
also available for patients with a standard ICD indication who 
also meet the above listed criteria. Using atrial-synchronized 
biventricular pacing in combination with optimal drug therapy 
has been shown to significantly improve patients’ symptoms.
R I G H T  V E N T R I C U L A R  A P I C A L  P A C I N G
R I G H T  V E N T R I C U L A R  A P I C A L  PA C I N G  A N D  I A T-
R O G E N I C  L B B B  ( I A T R O G E N I C  D Y S S Y N C H R O N Y )
Over the last few years, it became obvious that not only the 
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spontaneous LBBB is harmful for the patients, but the iatro-
genic LBBB produced by RV apical pacing is equally deleteri-
ous. The first-order pacing goal was resolution of bradycardia. 
Later on, atrial leads were added to establish AV synchrony. 
Pacing leads were designed for easy and reliable delivery to 
the RV apex and right atrial appendage, where the position is 
considered convenient and stable after years of clinical prac-
tice. There is strong evidence that long-term RV apical pacing 
might promote HF [28-31] and atrial fibrillation [28,30-33] and 
increase morbidity and mortality [29,31]. Animal and clinical 
data show that RV apical pacing results in asynchronous left 
ventricular activation and contraction [34-36]
Long-term RV apical pacing leads to: 1) Altered left 
ventricular electrical and mechanical activation; 2) Altered 
ventricular function, that means less work produced for 
given left ventricular end-diastolic volume and delayed pap-
illary muscle activation leading to valvular insufficiency; 3) 
Remodeling due to modified regional blood flow patterns, 
increased oxygen consumption without increase in blood flow 
(60% change in blood flow between early and later activated 
regions) and abnormal thickening of left ventricular wall; and 
4) Cellular disarray expressed as fibrosis (away from pacing 
lead location), fat deposition, calcification and mitochondrial 
abnormalities.
The electrical activation of the left ventricle differs when 
comparing sinus rhythm and RV apical pacing, the main dif-
ference being the presence of only a single break-out site on 
the left ventricular endocardium with apical pacing. Early work 
by Cassidy et al [37] showed that during sinus rhythm there are 
two break-out locations on left ventricular endocardium (in 
the inferior border of the mid-septum and the superior basal 
aspect of free wall), while latest activation takes place in the 
base of the inferior posterior wall due to muscular conduc-
tion (less Purkinje fiber density). Later on, work by Vassallo 
et al [38] showed that during RV apical pacing there is single 
break-out location on the left ventricular endocardium simi-
lar to LBBB, while latest activation is similar to the intrinsic 
(infero-posterior base) pattern.
The performance of the left ventricle is altered. While 
recent evidence has focused on altered left ventricular function 
with RV apical pacing in humans, earlier studies in animals 
suggested that pacing from the RV apex was not “optimal”. 
Note that some of these studies precede Medline. In 1925 Wig-
gers [2] stated that “the initial slower rise of intra-ventricular 
pressure is prolonged, isometric contraction phase is length-
ened, the gradient is not so steep, the pressure maximum is 
lower, and the duration of systole is increased.” He observed 
a double contraction process, artificial stimuli inducing lo-
cal fractionate contractions which mean slow conduction, 
whereas when the impulse reaches the Purkinje system the 
conduction is rapid. Later on in 1964, Lister [12] found greater 
reduction in cardiac output when pacing was performed from 
ventricular sites associated with longest total activation time 
due to muscle conduction. He also found conduction veloc-
ity differences: Purkinje= 2-4 m/s, muscle= 0.2-1 m/s. In 
1971 Boerth and Covell [39] found reduced left ventricular 
pressure, wall stress, and dP/dt despite normal perfusion. In 
1986 Burkoff [40] stated that the more muscle mass activated 
by muscle conduction rather than Purkinje conduction, the 
weaker the beat (theory of “ineffective muscle mass”), while in 
1988 Rosenqvist [41] noted increased incidence of congestive 
HF in ventricular paced patients.
Altered myocardial perfusion. In 1985 Heyndrickx and 
coworkers [4] found that the coronary blood flow was higher 
despite decreased cardiac output. Work by Prinzen (1990) 
[42] demonstrated that altered electrical activation of the left 
ventricle precipitates non-homogeneous left ventricular wall 
strain and, consequently, myocardial perfusion defects. He 
observed similarity in behavior of electrical activation, fiber 
strain and blood flow but redistribution of strain and blood 
flow with RV pacing (early activated regions ~60% blood flow 
of late activated regions), while the regions of the heart acti-
vated via the Purkinje system (simultaneous activation) have 
greater fiber strain and blood flow. In 1997 Tse and Lau [3] 
showed that long-term RV apical pacing resulted in high inci-
dence of myocardial perfusion defects that increased with the 
duration of pacing. These myocardial perfusion abnormalities 
were associated with wall motion abnormalities and impaired 
global left ventricular function.
Apical pacing histopathology: Altered strain patterns in 
the left ventricle can induce cellular and sub-cellular remod-
eling, as well as fibrosis and calcification. It is of note that 
this occurs a distance from the pacing lead location. Studies 
by Karpawich in 1990 [43] in pediatric canine model showed 
left ventricular myofibril disarray which was found after 4 
months of pacing from the RV apex (90 degree misalignment 
of adjacent fibers {stress related?}). He also noted appearance 
of prominent Purkinje cells in the subendocardium, variable-
sized mitochondria, and dystrophic calcification. In 1999 the 
same investigator [44] in pediatric patients, noted myofibril 
hypertrophy, intracellular vacuolation, degenerative fibrosis, 
and fatty deposits in the left ventricle after more than 3 years 
of RV apical pacing. The findings were independent of paced 
time, patient age, epi- or endocardial lead placement, and 
mode.
Human RV apical pacing studies have also been per-
formed. Those studies have noted impaired diastolic func-
tion (Betocchi et al [45], Bedotto et al [46], Stojnic et al [47]), 
reduced systolic contraction (Betocchi et al [45], Tse and Lau 
[3]), and altered myocardial perfusion (Tse and Lau [3]).
Recent clinical trials have drawn the same conclusion 
that pacing from the RV apex can lead to left ventricular 
dysfunction independent of pacing mode. The very impor-
tant MADIT-II study, except the very useful use of ICD in 
post-infarction patients with low EF which the study showed, 
importantly also showed that among these patients there was 
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a new or worsening of pre-existing HF [48]. The investigators 
observed that RV pacing causes ventricular dyssynchrony and 
may lead to worsening of preexisting HF or new appearance 
of HF. Other trials, like the DAVID Trial [29], the one by 
Sweeney et al [49], and the presentation by Steinberg [50], 
concluded that intrinsic ventricular activation is better for ICD 
patients with left ventricular dysfunction who do not “need” 
pacing. Taking into account that £10% of ICD patients have 
a class I pacing indication at the time of implant [51], physi-
cians, when appropriate, should consider ICD programming 
that avoids frequent RV pacing. In the DAVID trial [29], VVI 
(ventricular backup pacing mode) produced less than 3% ven-
tricular pacing and no atrial pacing, while dual chamber pacing 
produced around 60% of atrial and ventricular paced beats 
[52]. A MOST sub-study [30,49], focused on the relative risk 
of HF hospitalization in the DDDR group. The relative risk of 
hospitalization for HF was not decreased until the cumulative 
percent of ventricular pacing fell below 40%. Even if a physi-
cian was able to reduce the percentage of ventricular pacing 
from 85% to 45%, the patient’s relative risk for HF hospitaliza-
tion remained about the same. Below 40% ventricular pacing, 
for each 10% increase in cumulative percent pacing, there 
was an associated 54% relative increase in risk of HF hospi-
talization. Novel algorithms or pacing modes that attempt to 
reduce cumulative ventricular pacing should strive to reduce 
this percentage below 40%. If they are unable to achieve this 
degree of reduction, the relative risk for HF hospitalization 
is almost entirely unaffected. The Danish Pacemaker Study 
[53] compared AAI vs. VVI pacing for sick sinus syndrome: 
In the AAI pacing mode, patients had slightly better survival 
and this mode was associated with lower occurrence of HF 
(i.e. native AV conduction is better). The Pacemaker Selection 
in the Elderly study [54] compared VVI vs. DDD for sinus 
node dysfunction or AV block. They found no difference in 
quality of life or clinical outcome. The common observation 
of the 4 aforementioned studies was that ventricular pacing, 
not a lack of AV synchrony, was a more important predictor 
of left ventricular dysfunction.
P O S S I B L E  M E C H A N I S M S  F O R  T H E  A D V E R S E  
E F F E C T S  O F  R I G H T  V E N T R I C U L A R  A P I C A L  
PA C I N G
Pacing site affects left ventricular synchrony, as measured 
by left ventricular dysfunction (systolic and diastolic), remod-
eling (asymmetric septal hypertrophy, myofibril disarray, mo-
lecular remodeling), QRS duration, perfusion disturbances, 
and ventricular dilation.
Early work by Karpawich [43,55] demonstrated that, in 
contrast to RV apical pacing, RV septal pacing (with participa-
tion of the conduction system) does not result in myofibrillar 
disarray of the left ventricular free wall (in a canine heart). 
Specifically, during RV apical pacing he observed myofibrillar 
disarray in the left ventricular free wall histology in the canine 
heart. Contrariwise, septal pacing showed parallel orientation 
in the left ventricular free wall histology [43,55].
Figure 1 shows the “Wiggers” diagram of hemodynam-
ics and steps through the left ventricular pressure-volume 
(LV-PV) loop. At the beginning of the cardiac cycle, both 
pressure and volume in the ventricle are low at the time of 
mitral valve opening (MVO). During left ventricular filling, 
volume increases and pressure stays relatively low. Once the 
ventricle has depolarized and begun to develop pressure, 
the mitral valve closes (MVC). The ventricular pressure 
then increases dramatically with no change in volume as the 
ventricle prepares for ejection during isovolumic contraction. 
Eventually, left ventricular pressure exceeds arterial pressure 
and the aortic valve opens (AVO) and ejection proceeds. Left 
ventricular pressure remains high during ejection as volume 
decreases. As relaxation ensues, left ventricular pressure drops 
below aortic pressure and the aortic valve closes (AVC). Fi-
nally, isovolumic relaxation continues as the ventricle actively 
relaxes in preparation for the next filling cycle. The area inside 
FIGURE 1. Here is depicted the “Wiggers” diagram of hemo-
dynamics and steps through the left ventricular (LV) pressure-
volume (P-V) loop. At the beginning of the cardiac cycle, both 
pressure and volume in the ventricle are low at the time of mi-
tral valve opening (MVO). During LV filling, volume increases 
and pressure stays relatively low. Once the ventricle has depo-
larized and begun to develop pressure, the mitral valve closes 
(MVC). The ventricular pressure then increases dramatically 
with no change in volume as the ventricle prepares for ejection 
during isovolumic contraction. Eventually, LV pressure exceeds 
arterial pressure and the aortic valve opens (AVO), and ejection 
proceeds. LV pressure remains high during ejection as volume 
decreases. As relaxation ensues, the LV pressure drops below 
aortic pressure and the aortic valve closes (AVC). Finally, iso-
volumic relaxation continues as the ventricle actively relaxes in 
preparation for the next filling cycle. The area inside the loop 
is known as “Stroke Work,” and is equal to the work performed 
by the LV to eject the stroke volume. The width of the P-V loop 
is the “Stroke Volume”. Proper interpretation of the shape of 
the LV P-V loop can provide insights into changes in systolic 
and diastolic left ventricular function, preload, afterload, and 
synchrony of LV contraction.
164
HOSPITAL CHRONICLES, SUPPLEMENT 2006 IATROGENIC LBBB/ALTERNATE SITE PACING
165
the loop is known as “Stroke Work,” and is equal to the work 
performed by the left ventricle to eject the stroke volume. The 
width of the P-V loop is the “Stroke Volume”. Proper inter-
pretation of the shape of the left ventricular loop can provide 
insights into changes in systolic and diastolic left ventricular 
function, preload, afterload, and synchrony of left ventricular 
contraction.
In figure 2, PV loop analysis from 13 patients with normal 
left ventricular function is shown. Data were collected [56] 
from 13 patients during acute atrial overdrive pacing (AAI), as 
well as during dual chamber pacing, with different ventricular 
activation sites including His, RV apex, RV free wall (RVFW), 
RV septum, and a single left ventricular site. All loops were 
collected at the same overdrive heart rate with a short AV delay 
(atrium to His delay –10 ms). The patient shown, had normal 
ejection fraction and no history of HF. Looking at the loops, 
the following main points are made: (1) Left ventricular func-
tion changes with pacing site as evidenced by changes in the 
width of the loop. Interestingly, the optimal site of pacing may 
vary with different patients, that is, there is no “sweet spot”; 
(2) In this patient, with normal left venrtricular function, RV 
septal pacing appears to be hemodynamically superior to RV 
apical or RV free wall, and somewhat inferior to left ventricu-
lar-only pacing. This relatively subtle difference may partially 
explain the results of the pacing mode trials (DANISH [31], 
CTOPP [32], MOST [33], etc.) that required long duration 
follow-up to show a difference. Note that those trials were all 
performed in relatively healthy populations. Also, these data 
may explain why the acute and short-term randomized pacing 
site trials had equivocal results [57].
In sharp contrast to the above data, the data shown in 
figure 3 are from another patient in the same study [56]. 
This patient, with severe left ventricular dysfunction, shows 
an increased sensitivity to pacing site. Note the distortion in 
the baseline (AAI) loop compared to the previous figure, in-
dicative of left ventricular dysfunction. Imagine if this patient 
had received chronic pacing at the RV apex!
The negative inotropic effect [4,40,41,58] secondary to RV 
apical pacing has been confirmed using magnetic resonance 
imaging (MRI) tagging techniques to be secondary to abnor-
mal activation and contraction of the heart [59]. In addition, 
RV pacing has a disadvantageous effect on maximum venous 
consumption uptake and cardiac efficiency [60]. These data 
may further clarify the dramatic results of the DAVID trial, 
because the ICD population studied in that trial had poor left 
ventricular function [29].
Numerous acute and chronic clinical studies have been 
conducted to compare the hemodynamic differences between 
RV-apical-paced and RV outflow tract (RVOT)-paced pa-
tients, yet the results vary. However, unlike the pacing mode 
trials, most of these studies were in small and varying popula-
tions with no precise verification of the actual lead placements 
in the RVOT and, importantly, follow-up in most trials was 
quite short [61].
What are the alternatives? While from the previous results 
it appears that RV pacing in general is deleterious, this is 
FIGURE 2. P-V loop data from patients during acute atrial 
overdrive pacing (AAI) and during dual chamber pacing from 
different ventricular pacing sites including pacing at the His 
bundle, RV apex, RV free wall, RV septum, and the left ven-
tricle (LV). All loops were collected at the same overdrive heart 
rate with a short AV delay (atrium to His delay –10 ms). In these 
cases the ejection fraction is normal and there is no history of 
heart failure.
FIGURE 3. In sharp contrast with the data in the previous 
figure, these data are from patients with severe left ventricular 
dysfunction, and show an increased sensitivity to the pacing 
site. Note the distortion in the baseline (AAI) loop compared 
to figure 2, indicative of left ventricular (LV) dysfunction. One 
can well imagine the consequences of chronic pacing at the 
right ventricular (RV) apex in such a patient! These data may 
further clarify the dramatic results of the DAVID trial, as the 
ICD population studied in that trial had poor LV function.
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not true. There is data to suggest that pacing at or near the 
His-Purkinje system can normalize left ventricular electrical 
and mechanical activation [62]. Dr. Wiggers [2] stated that 
the shorter the distance for the impulse to travel to reach the 
Purkinje system, the more effective the contraction. During 
direct ventricular stimulation, the contralateral ventricle 
contracts more effectively than the stimulated ventricle. 
Contraction patterns can be normalized with pacing despite 
increased dispersion of activation; duration of contraction is 
not affected with pacing [39]. Once the electrical activation 
reached the Purkinje system, the remaining fibers are acti-
vated quickly. This is different from LBBB, while electrome-
chanical delay was longer but contraction time was shorter 
with pacing [63].
Recognition of the chronic adverse effects of RV pacing 
has stimulated interest in strategies to either reduce or attenu-
ate these effects. Of the approaches listed, each one, with the 
exception of perhaps the managed ventricular pacing (MVP) 
and AAISafeR modes, has inherent risks and/or programming 
interlocks associated with programmable parameters associ-
ated with it. There are several conventional approaches to 
minimization of ventricular pacing. These are single chamber 
AAI(R) pacing, which eliminates the possibility of ventricular 
pacing with its attendant risks and consequences; VVI(R) 
pacing which eliminates the possibility of AV synchrony and 
physiologic chronotropic support; and manipulation of dual 
chamber mode timing cycles to minimize unnecessary ven-
tricular pacing at the RV apex. Finally, new, unconventional 
approaches to manage ventricular pacing via smart “modes” 
such as the MVP and AAISafeR modes which operate as 
smart mode switch algorithms that continuously monitor 
loss or restoration of conduction and can dynamically switch 
between AAI(R) operation and DDD(R) operation.
A L T E R N A T E  S I T E  P A C I N G
The ultimate objective of pacing is to achieve chronic res-
toration of normal cardiac function. Over the decades, several 
tools have been developed to achieve this goal, including pac-
ing algorithms, devices, and leads. Selective site RV pacing 
has been suggested as an approach to reduce the incidence of 
ventricular dysfunction, atrial arrhythmias, and to influence 
morbidity resulting from asynchronous left ventricular activa-
tion emanating from traditional RV apex pacing. Pacing from 
the RV apex allows a stable ventricular rate and enables repro-
duction of AV synchrony but does not reproduce physiologic 
activation of the left ventricle. Studies have also demonstrated 
that lead placement in non-traditional atrial sites reduces the 
frequency of symptomatic atrial tachyarrhythmia episodes, 
especially when combined with preventive algorithms [64]. 
For wider adoption of selective right atrial and RV site pac-
ing, the pacing community will require reliable benchmark 
clinical outcomes trials and validation of the ability for safe 
and efficient implants.
Cardiac pacing was envisioned originally to treat hemo-
dynamic instability thought to result from a lack of cardiac 
output due to a low ventricular rate. Advances in the field of 
cardiac physiology have established that cardiac output is not 
dependent solely on ventricular rate, but the combination of a 
physiologic heart rate, atrial contribution, and left ventricular 
activation sequence, all impacting upon the function of the left 
ventricle. Cardiac pacing utilizing electrical stimulation has 
evolved in an attempt to reproduce these physiologic param-
eters and hence to re-establish physiological left ventricular 
function. Extrinsic electrical stimulation can be defined in four 
principal targets: re-establishing stable heart rate, restoring 
AV synchrony, achieving chronotropic competence (rate-re-
sponse) and normal physiologic activation and timing patterns. 
All four of these targets are based on the expectation that safe 
and reliable electrical therapy is available at all times.
Target 1: Re-establishing the heart rate. Initially, the goal 
of pacing was establishment of a stable ventricular rhythm. 
Early pacing candidate patients had AV block and were treated 
with single site ventricular pacing. Initially, pacing was limited 
to a fixed rate due to available technology, but technological 
advancements evolved to allow demand pacing. Pacing lead 
technology initially required epicardial placement, but evolved 
to allow endocardial implants with reliable electrical perfor-
mance and stability in the RV apex [1,54,65,66].
Target 2: Restoring AV synchrony. Developments in am-
plifier and sensing technology, along with improvements in 
lead design and materials, created the first opportunities for 
restoring AV synchrony. This was achieved by either pacing the 
atrium or sensing and tracking its intrinsic activity. Either of 
these events triggered a programmable duration of AV delay 
after which, if intrinsic ventricular activity was not sensed, 
the lower chamber was paced. These developments resolved 
most cases of pacemaker syndrome and offered physiologic 
rate variation for those patients with a stable, trackable atrial 
rhythm. Unfortunately, these attributes also opened the door 
to a new problem: pacemaker-mediated tachycardia. Also, 
although the atrium could be paced, no therapy was available 
for atrial fibrillation. At the time, the phrase “physiologic pac-
ing” [66] was coined but, in retrospect, use of the term may 
have been premature, particularly for patients with a high 
degree of heart block.
Target 3: Achieving chronotropic competence (rate-re-
sponse). Sensors that detected the need to change pacing 
rates enabled pacemakers to respond to patient metabolic 
needs and improved patient exercise capacity. The quality of 
life benefits of these sensor-driven, rate-responsive devices 
were quickly demonstrated. With the introduction of rate re-
sponse, the technical issue of delivering an electrical charge 
that depolarizes the atria and ventricles at the appropriate time 
has been resolved from a practical standpoint. However, this 
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treatment modality has not resulted in all patients receiving 
a satisfactory level of cardiac function and chronic stability. 
It has remained difficult to differentiate the benefits of rate 
response from those of AV synchrony, even in very recent 
studies [54,67]. Consequently, attention is focusing on the 
reasons for failing to demonstrate the expected benefits of 
“physiological pacing” and is shifting from the simple electri-
cal aspects of pacing towards the functional effects of the way 
in which therapy is delivered.
Target 4: Achieving normal physiologic activation and tim-
ing patterns. Examination of some long-term effects of pac-
ing from traditional sites has begun to reveal non-physiologic 
aspects of current approaches. Producing normal heart rates 
and AV delays on the surface ECG is not enough. We must 
now look closely at the entire depolarization pattern through 
all four chambers of the heart, as well as the functional effects 
of stimulating and sensing from different sites within the atria 
and ventricles. Initiation of electrical activation in the right 
atrial appendage may result in significant activation delay for 
the left atrium, with consequent effects on timing between left 
atrial and left ventricular contraction. Pacing the ventricles at 
the RV apex compounds this effect. In addition, ventricular 
contraction patterns associated with pacing at the RV apex 
can exhibit significant variations in ventricular muscle strain 
as well as left/right discoordination and longer depolarization 
times [35].
Recent clinical data have demonstrated that RV apical 
pacing alone, independent of pacing mode, can lead to left 
ventricular dysfunction. In the DAVID trial [29] it was noted 
that in ICD recipients with prior left ventricular dysfunction, 
low rate (40 bpm) single chamber ventricular pacing (VVI-40) 
was associated with less deleterious effects than dual chamber 
pacing at a nominal rate of 70 bpm (DDDR-70). Additionally, 
the MOST trial [30,49], in which all RV leads were placed at 
the apex, revealed that single-chamber atrial pacing in patients 
with sick sinus node was associated with a lower incidence of 
hospitalization related to symptoms of congestive HF than 
patients who received dual-chamber pacemakers. Similarly, 
in a prospective 3-year follow-up study by Nielsen et al [68], it 
was reported that patients with sick sinus node randomized to 
DDDR pacing, independent of AV delay, exhibited increased 
left atrial dilation and a higher incidence of atrial fibrillation, 
compared with those patients randomized to single-chamber 
atrial pacing. So, the need for alternate site pacing is obvious. 
Current technologies in cardiac pacing have successfully met 
three of the four stated targets: establishing stable and physi-
ologic heart rate, and enabling AV synchrony. The fourth goal, 
achieving normal physiologic activation and timing patterns 
has yet to be attained. The use of selective pacing sites may 
achieve this goal and may result in improved left ventricular 
performance with reduction or avoidance of left ventricular 
remodeling [69]. Selective site pacing additionally may reduce 
atrial tachyarrhythmias.
Pacing Sites: Traditional, Alternate and Selective. Tradi-
tionally, the right atrial appendage and RV apex are used as 
pacing sites because they allow easy endocardial placement 
of leads while providing stable and reliable chronic pacing 
parameters. Although these sites maintain heart rates and 
AV synchrony, RV apical pacing is associated with increased 
morbidity and mortality relative to native AV conduction 
[29,30,41,45,49,68]. Right ventricular apical pacing initiates 
an abnormal asynchronous electrical activation pattern 
which results in asynchronous left ventricular contraction 
and relaxation [4,45-47,70]. Consequently, RV apical pacing 
can lead to inhomogeneous left ventricular wall strain [42], 
myofibrillar disarray [43,44,71], and pathological perfusion 
defects [3,4,42,70] with resultant increases in congestive HF 
and mortality.
The term “alternate site pacing” refers to sites other than 
the right atrial appendage or RV apex. Implicit with the phrase 
“alternative site pacing” was the false notion that one was opt-
ing to alter from a proven standard care pacing; i.e., RV apex 
or right atrial appendage. The term “selective site pacing” 
has been proposed as more accurately reflects the physician’s 
rationale for where he chooses to implant a pacing lead(s). 
The physician selects a specific pacing site for a variety of 
potential benefits. In the atria, the specific site is selected to 
reduce intra-atrial conduction delays and minimize dispersion 
of refractoriness which improves clinical syndromes and their 
associated disease states such as refractory atrial tachycardias 
and paroxysmal atrial fibrillation, as well as reduction of other 
adverse effects of traditional pacing [72]. These include im-
provement of depolarization patterns, hemodynamics, sens-
ing and efficacy of atrial tachyarrhythmia/atrial fibrillation 
therapy. Site selection also allows minimization of far-field 
right wall sensing. In the ventricles, expected improvements 
from a more physiologic depolarization pattern include better 
hemodynamics [61], less mitral valve regurgitation and less 
remodeling [73], as well as delaying, reducing, or eliminating 
long-term negative changes such as perfusion defects and 
heart failure [55,70].
S T A N D A R D I Z A T I O N  O F  S E L E C T I V E  
S I T E  P A C I N G
Numerous acute and chronic clinical studies have been 
conducted to compare the hemodynamic differences between 
RV apical and RVOT paced patients, yet, the results vary. 
It should be noted that in only one study was it found that 
RVOT pacing was hemodynamically worse than RV apical 
pacing [61]. Among 17 studies (acute and chronic) compar-
ing the hemodynamic differences between RV apical and 
RVOT paced patients, 8 studies favor RVOT pacing; 1 study 
had negative results for RVOT vs RV apical pacing, while 8 
studies found no difference between the two sites. Why do the 
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results vary? There are many differences among the studies: 
varied patient populations, non-physiological pacing (VVI 
not DDD), arbitrary AV delays in DDD pacing (similar for 
RV septal and RV apex pacing; normally there is a 30-50 
ms delay in conduction between these sites), co-morbidities, 
varied or unknown EF and QRS duration. But the most im-
portant factor seems to be the location of the ventricular paced 
lead. The term RVOT is used arbitrarily and the location in 
RV septum and RVOT is unknown, which means a precise, 
uniform definition is needed.
As researchers have attempted pacing from other areas 
of the heart, they have been hindered by the lack of uniform 
definitions of preferred pacing sites and the inadequacy of 
tools to consistently reach those locations and verify correct 
placement [69]. In addition, this lack of definition consensus 
may have contributed to the apparent conflict of data. Without 
these advances, variations between patients will make proving 
the advantages of selective site pacing difficult, if not impos-
sible. Therefore, there is need for standardization of terms and 
identifying measures for selective pacing sites.
Traditionally, when defining new pacing sites in the heart, 
the literature has defined anatomical positions. These sites 
are very difficult to visualize and verify using electrophysiol-
ogy laboratory tools. There is a need to correlate anatomical 
sites with fluoroscopy and EGG tracings. Thus, using tools 
available at implant and in the electrophysiology laboratory, 
the physician is able to accurately reach and verify selective 
pacing sites. Using selective site pacing, a variety of additional 
sites in the atrium or ventricle may be used for lead placement 
to achieve various potential benefits.
Right Atrial High Septum: To address improvement of 
physiological activation and perhaps prevent atrial fibrillation, 
leads may be placed at the high right atrial septum, either in 
the crista terminalis or in Bachmann’s bundle, a group of 
muscular fibers that originate in the crista terminalis. This 
atrial muscle tissue has high conduction velocity but lacks 
distinct electrophysiological properties. EGG criteria for 
this approach are positive or isoelectric P waves in leads II 
and III [72].
Right Atrial Low Septum (Coronary Sinus Ostium): 
Atrial activation has been shown to be a determinant in the 
predisposition to atrial fibrillation. It has been shown that 
coronary sinus ostium pacing shortens the duration of atrial 
activation [74], which may decrease one’s propensity to acquire 
atrial fibrillation. In a left anterior oblique (LAO) 400 view, 
the area just superior to the coronary sinus ostium, inferior 
to the foramen ovale is the target for pacing. If the coronary 
sinus-left atrium is viewed as a clock face, the coronary sinus 
os is at the 6 o’clock position and the tip, when appropriately 
advanced, will be at the 12 o’clock position. On the fluoro-
scopic image, lead position corresponds to the right atrial 
region contiguous with the coronary sinus ostium. The EGG 
criterion for this approach is a negative paced P wave in leads 
II, III and aVF.
Right Ventricular Outflow Tract (RVOT): The implant-
ing electrophysiologist and cardiologist have rather loosely 
used the term RVOT to refer to a poorly defined broad area 
of the RV, which has come to include all areas except for the 
RV apex.
RVOT Anatomical Definition: We define the lower bor-
der of the RVOT as a line drawn parallel to the RV inferior 
border, extending from the apex of the tricuspid valve (His) 
to the border of the RV in an antero-posterior (AP) view. The 
anatomical RVOT upper border is defined as the pulmonary 
valve. These boundaries form a trapezoid-shaped area, whose 
remaining borders would be the interventricular septum and 
RV free wall in the left anterior oblique (LAO) view. Utilizing 
standard fluoroscopy, one cannot visualize the exact RVOT 
landmarks provided by the described anatomical model. 
Therefore, one must use fluoroscopic images and EGG pat-
terns that would correlate with these same areas defined by 
the anatomical model.
RVOT Fluoroscopic Definition: The RVOT anatomical 
lower border is demarked on fluoroscopy by extending a pacing 
catheter parallel to the RV inferior border from the tricuspid 
valve apex (His) to the RV border in the AP or right anterior 
oblique (RAO) view. This catheter correlates with the lower 
border of the anatomical RVOT. The upper border of the 
anatomical RVOT is determined on a fluoroscopic image 
by positioning a pacing catheter through the pulmonic valve 
(noted by loss of R-wave on the intracardiac electrogram). The 
junction of the RV and pulmonary artery is identified by the 
appearance of large R-waves as the catheter is withdrawn into 
the right ventricle. This correlates with the pulmonic valve, 
which is the upper border of the anatomical RVOT. The above 
method demonstrates how to correlate the anatomically de-
fined RVOT via a fluoroscopic image. The next goal is to 
define specific anatomical sites within the RVOT area.
Defining Specific RVOT Sites: For simplicity, the RVOT 
can be divided into four quadrants. The RVOT is divided 
horizontally in half by a line halfway between the pulmonic 
valve and lower border (connected from the RV septum to the 
RV free wall), forming an upper and lower half. The RVOT is 
divided vertically in half by a line that connects the pulmonic 
valve to the RVOT lower border; i.e., dividing the RVOT into 
a RV septal and RV free wall area. This classification defines 
high and low RVOT septal positions and high and low RV free 
wall positions. The LAO 400 fluoroscopic view is utilized to 
help differentiate the RVOT septum and free wall (Figures 
4-6). EGG confirmation of pacing in the RV septum is mani-
fested by a negative QRS morphology in lead I (Figure 5), 
whereas pacing in the RV free wall manifests as a positive 
QRS morphology in lead I. Use of the RAO view helps to 
guide high and low positions. A high position will result in an 
upright QRS in aVF, and lower positions will have less positive 
QRS deflections in aVF (Table 1, Figure 5).
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FIGURE 4. An LAO 30° view during ICD implantation in one 
of our own patients. The active fixation right ventricular (RV) 
pacing/defibrillation lead is located in the low septum of the RV 
outflow tract (see text for details).
FIGURE 5. An LAO 30° view during biventricular pacemaker im-
plantation and alternate site right ventricular (RV) pacing, in one 
of our own patients. The active fixation RV lead is located in the 
low septum of the RV outflow tract (RVOT). This site was selected 
and confirmed by fluoroscopy and ECG criteria (QRS complex 
negative in lead I and isoelectric in lead aVF). Note the width 
of the QRS complex in the 12-lead ECG, it is almost normal 
(at baseline the patient had a QRS >180 ms). Coronary sinus 
venography is presented where the target vein (lateral branch) is 
easily accessed with use of an over-the-wire left ventricular (LV) 
lead system. The combination of RV alternate site pacing and 
biventricular pacing has not been examined in the literature, but 
according to our experience it seems to work better.
B E N E F I T S  O F  A L T E R N A T E  S I T E  P A C I N G
A T R I A L  T A C H Y A R R H Y T H M I A S
Significant data have already demonstrated that lead 
placement in the atrial septal site reduces the frequency of 
symptomatic atrial tachyarrhythmia episodes, especially when 
combined with prevention algorithms [64]. It has also been 
shown that high septal lead placement delays the time to devel-
opment of chronic atrial fibrillation [72]. Additional research 
indicates the use of atrial septal lead placement may reduce 
P-wave duration and decrease the dispersion of refractoriness 
[74]; may reduce AV conduction time and potentially facilitate 
more intrinsic conduction [74], and may prevent paroxysmal 
atrial fibrillation in symptomatic patients who are refractory 
to antiarrrhythmic drugs [75]. Other benefits are also being 
investigated. It is believed atrial anti-tachyarrhythmia pacing 
should be more effective from the atrial septal site since it is 
closer to the left atrium. It is thought that many atrial flutters 
are atypical and originate from the left atrium. In addition, 
detection of atrial tachyarrhythmias may be better from the 
atrial septum, as it may reflect true atrial tachyarrhythmia. 
Right atrial appendage electrograms tend to be more orga-
nized and stable, while right atrial appendage leads are more 
likely to classify atrial fibrillation as atrial tachycardia for 
this reason.
Based on current data, it is anticipated that the standard 
of care will use lead placement in the mid/high region of the 
atrial septum for a variety of benefits. However, the ability 
to explore specific atrial pacing sites may result in modified 
recommendations in the future.
Ventricular Hemodynamic Performance: The use of RV 
selective site pacing could be more beneficial than the RV 
apical pacing currently used for treating bradycardia. Potential 
negative effects of RV apical pacing have been discussed as 
early as 1925 [2,38,76], and a recent trial has indicated that 
RV apical pacing should be avoided [29]. Abnormal activation 
patterns that result from RV apical pacing can cause changes 
in collagen and myocardial fibrous tissue content, resulting 
in remodeling and cellular damage. Over a period of several 
years, left ventricular dysfunction and cardiac failure can oc-
cur. In contrast, RV selective site pacing in the RVOT/septal 
region may provide better therapy including more physiologic 
depolarization and activation patterns in both the atrium and 
TABLE 1. QRS morphology related to different RVOT 
sites
RV Alternate Site Pacing Lead I Lead aVF
High Septal (-) (+)
Low Septal (-) (±)
High Free Wall (+) (+)
Low Free Wall (+) (±)
RV= right ventricle; RVOT= right ventricular outflow tract
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ventricle [3,35,44]. Selective site pacing could be particularly 
beneficial for young patients, active elderly patients and those 
patients with left ventricular dysfunction, offering the clinician 
the opportunity to select pacing sites and optimize therapy 
for each individual patient. In the area of resynchronization, 
the introduction of biventricular pacing for heart failure has 
proven the value of tailoring a patient’s depolarization pattern 
by choosing the appropriate activation site(s). For other pacing 
patients, it must be determined whether selective site pacing 
will improve left ventricular performance by maintaining 
synchrony. A better understanding of left atrial activation is 
needed in order to predict its improvements in left atrial and 
left ventricular timing and its contribution to left ventricular 
filling. The combination of synchrony and a physiologic activa-
tion sequence may lead to improved hemodynamics.
R E V I E W  O F  P R I O R  S T U D I E S  O N  A L T E R N A T E  
R I G H T  V E N T R I C U L A R  PA C I N G  S I T E S
Introduction of newly designed active fixation (screw-in) 
pacing electrodes has enabled lead implantation into differ-
ent regions of the right ventricle [69]. In an effort to identify 
an optimal pacing site that will not worsen cardiac function, 
alternative sites in the right ventricle have been proposed: (l) 
RVOT, septal [77] and in the free wall [78,79], (2) the His-bun-
dle [80,81], and (3) bifocal RV pacing [61,82-86]. The results 
of studies evaluating alternative pacing sites in the RV have 
given conflicting and controversial results. However, attempts 
to evaluate the clinical impact of alternative pacing sites suffer 
from a paucity of clinically relevant criteria to quantify this 
impact. Most studies published so far use relatively “soft” 
surrogate endpoints (e.g., quality-of-life, 6-minute walking 
test, NYHA classification, acute hemodynamic impact, QRS 
width, etc.). These parameters are not considered by many as 
sufficiently robust for exact quantification of the true clinical 
benefit, and mortality data are not available on a larger scale. 
This should not be considered as a weakness of the study 
but rather as a reflection of lack of parameters allowing for 
a more subtle evaluation of the severity of the syndrome of 
heart failure in its course in an individual patient.
Schwaab et al [87] showed in an acute study that QRS nar-
rowing produced by RVOT pacing compared with RV apical 
pacing was associated with homogenization of left ventricular 
activation and an increase in left ventricular systolic func-
tion. A similar acute hemodynamic improvement produced 
by RVOT pacing was described by Giudici et al [78]. De Cock 
et al [88] observed superiority of RVOT pacing in terms of 
the cardiac index in patients without structural heart disease. 
However, some patients with a reduced left ventricular EF 
<0.50 or advanced coronary artery disease had a decreased 
cardiac index during RVOT pacing. In contrast, Buckingham 
et al [89] demonstrated only nonsignificant increase of dP/dt 
during single site RVOT and simultaneous RV apical and 
RVOT pacing as compared with single site RV apical pac-
ing.
During midterm follow-up, Victor et al [82] found neither 
substantial change in functional class nor hemodynamic ben-
efit during RVOT pacing as compared with RV apical pacing. 
Conversely, Tse et al [70] compared both types of stimulation 
at 18 months and demonstrated that patients with RV apical 
pacing presented more often with pacing-induced regional 
wall-motion abnormalities than those with stimulation of 
the interventricular septum corresponding with the RVOT. 
Interestingly, no significant difference in prevalence of re-
gional wall-motion abnormalities was present earlier during 
follow-up (at 6 months).
There are three possible explanations for these mixed 
results: (1) a short duration of follow-up could explain the 
inconclusive results of previous clinical studies; (2) the lead 
position in the RVOT could have also influenced the results. 
The exact position was not explicitly specified in some of them. 
Of note, most of the previously mentioned studies described 
lead position using x-ray images and only some of them identi-
fied the final lead position using pacing-induced QRS width 
[70,82,87,89]. The pacing lead in these studies was implanted 
in the region with the narrowest QRS complex during pacing. 
(3) Finally, pacing-induced acute changes in hemodynamic 
performance do not necessarily predict hemodynamic im-
provement during long-term pacing.
Some of the variability in the results of these studies can be 
FIGURE 6. Here is shown alternate site pacing in the right atrium 
(interatrial septum) and the right ventricle with direct His bund-
le pacing, in a patient with sick sinus syndrome and normal 
left ventricular (LV) function. In both chambers active fixation 
pacing leads of novel technology (lumenless/steroid-eluting) are 
used in both chambers. The fluoroscopic view is shown in (c) and 
(d) in anteroposterior (AP) and left anterior oblique (LAO) 
30° views respectively. In (a) and (b) AAI and DDD pacing are 
shown. Note the narrow QRS complex during DDD pacing with 
short AV delay. The patient did not have AV conduction distur-
bances (Kappos KG, Manolis AS, et al: unpublished data).
170
HOSPITAL CHRONICLES, SUPPLEMENT 2006 IATROGENIC LBBB/ALTERNATE SITE PACING
171
explained by the strong likelihood that different investigators 
were pacing at different sites in the RVOT. Based on mapping 
data, it appears that when you pace from the higher RVOT, 
you are farther away from the His-Purkinje system. The ideal 
position seems to be pacing from the mid-septum, where the 
earliest endocardial signal, often with a potential from the 
right bundle can be observed. This is at the level of the His-
Purkinje system or lower (i.e., the beginning of the RVOT). 
This is reflected by the narrowest QRS complex as compared 
to the RV apex or high RVOT pacing (Figure 6).
In contrast, pilot studies evaluating combined pacing at 
more than two sites demonstrated a positive impact of multi-
site pacing on cardiac output in patients after cardiac surgery 
[90] or with congestive heart failure [91]. The results of such 
studies evoked interest in biventricular pacing.
Stambler et al [85] conducted a randomized, crossover 
multicenter study of RVOT pacing compared to RV apical 
pacing. This trial included 103 patients with chronic atrial 
fibrillation and EF <0.40 with 3 months of pacing at each 
site and quality-of-life endpoint. RVOT pacing shortened 
the QRS duration in this study, but did not improve quality-
of-life or other clinical outcomes. This study had a follow-up 
period that was shorter than that used in the trials of left 
ventricular pacing [92-102]. Using a Cochrane search strategy, 
nine studies of RVOT pacing were identified by de Cock et al 
[65]. The results of these studies (217 patients) were pooled 
and showed a significantly better hemodynamic effect (odds 
ratio 0.34) compared to RV apical pacing. This suggests that 
this approach may offer a mildly beneficial effect compared 
to ventricular pacing at the standard location.
H I S - B U N D L E  PA C I N G
His bundle pacing has been of theoretical interest for many 
years. The idea of delivering a pacing impulse directly into the 
cardiac conduction system is attractive because of the possible 
hemodynamic benefits that could be obtained by a normal 
activation sequence. However, the small size and anatomic 
position of the His bundle have made this approach difficult. 
The first attempts at direct His-bundle pacing were performed 
in dogs and used transthoracic access [103,104]. Transvenous 
His-bundle pacing in humans was performed for the first time 
in 1970 using a multipolar catheter [105]. However, catheter 
instability during cardiac contraction and para-Hisian pacing 
presented significant challenges. In 2000 and 2004, Deshmukh 
et al [62,80] described a significant reduction of left ventricular 
end-systolic and end-diastolic diameter, improvement of left 
ventricular EF, and in NYHA class during permanent direct 
His-bundle pacing in 14 patients with a narrow QRS (<120 
ms), chronic atrial fibrillation, and depressed left ventricular 
EF (<0.40). Hemodynamic improvement could be substan-
tially influenced by rate control and rhythm regularity, more 
than by pacing site. Another important question is if the pa-
tients with chronic HF and intraventricular delay will benefit 
from His-bundle pacing as much as from biventricular or 
single site left ventricular pacing. Yamauchi et al [106] showed 
decreased mitral regurgitation and improved hemodynamics 
acutely using direct His bundle pacing. In addition, Vazquez 
et al [107] have published a multipatient study validating the 
concept and duplicating the findings by Deshmukh et al. In 
an effort to improve the success rate of direct His bundle pac-
ing, echocardiography has been used to guide the permanent 
pacemaker lead to the region of the His-bundle. Although this 
has been successful in animals [108], only temporary pacing 
has been achieved in humans [109]. Figure 6 shows such a 
case of direct his bundle pacing from our department. Future 
studies and wide acceptance of this pacing site would depend 
on the development of better tools, including delivery systems 
and specialized leads with possibly a longer helix capable of 
stimulating not only the His-bundle but the His-Purkinje 
system on the right and left side of the septum.
D U A L  S I T E  ( B I F O C A L )  R I G H T  V E N T R I C U L A R  
PA C I N G
Besides anecdotal reports, there is only one medium sized 
study (n=39) in patients with dilated cardiomyopathy and con-
ventional pacemaker indication for chronic AV block which 
found a significant and remarkable improvement in systolic 
and diastolic left ventricular function together with a reduc-
tion in QRS duration when pacing from the RV apex and the 
RVOT simultaneously [110]. Other systematic approaches to 
bifocal RV stimulation in patients with different degrees of 
left ventricular dysfunction did not show significant improve-
ment over single site pacing either from the apex or the RVOT 
[85,89,111-113]. This applies to hemodynamic measurements 
and quality of life scores. The only consistent finding was 
a shortening of the QRS duration if increasing numbers of 
RV sites were paced together [111]. Although there was a 
significant correlation between the changes in paced QRS 
and cardiac output with dual site stimulation [112] in one 
report, this did not transfer into a beneficial effect for the 
whole group. In a recent study [114], a single-center experience 
was reported with CRT utilizing a protocol that specifically 
required the implantation of a bifocal RV lead system when 
pacing could not be adequately achieved from a lateral left 
cardiac vein. They found that, when biventricular CRT can-
not be achieved, a bifocal RV system confers similar benefits 
at 6 months [114]. CRT increases AV, as well as inter- and 
intra-ventricular synchrony. In the acute setting, the bifocal 
RV system can be expected to have similar effects on AV 
synchrony. This particular study [114] showed an immediate 
decrease in degree of mitral regurgitation with the bifocal 
RV system, perhaps from greater interventricular synchrony, 
in particular at the level of the interventricular septum. The 
bifocal RV system is not capable of recruiting the delayed 
lateral wall of the left ventricle. This was evidenced by the less 
pronounced improvement in wall motion observed with the 
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bifocal RV system than with the biventricular system, a clear 
deficiency of this approach. At 6 months, however, overall 
resynchronization improves with the bifocal RV system, per-
haps from ventricular remodeling. The authors concluded that 
their nonrandomized observational study suggests that clinical 
improvements conferred by biventricular stimulation can be 
matched in selected patients by implanting a bifocal RV sys-
tem. While the bifocal RV system should not be chosen as an 
initial treatment method, it may be an acceptable alternative 
in patients who have undergone unsuccessful left ventricular 
lateral vein implantation attempts (Figure 7) [114].
C O N C L U S I O N  A N D  R E C O M M E N D A T I O N S
Selective site pacing [116] may help achieve the long-term 
goal of normal physiologic activation and timing patterns. In 
addition, it may address the challenges that can result from 
traditional pacing. While critical research lies ahead, this 
technological breakthrough holds significant promise.
Where does this leave us? More chronic studies with more 
selective patient criteria are needed. Access and placement 
of leads in the RVOT/septum is feasible. When RVOT was 
used for pacing because the apex was inadequate (perfora-
tion, high threshold, diaphragmatic stimulation, problematic 
sensing, etc.), there was no lead-related electrical differences 
from apical pacing. Location of leads in alternate sites needs 
to be better documented. Antero-posterior and oblique images 
are needed to compare sites. Role of paced QRS duration 
in hemodynamic function needs clarification. More data are 
needed to confirm contribution of AV delay to hemodynamic 
function with alternate site pacing. Individual optimization 
may be the best approach. Patients with normal ventricular 
conduction distal to the AV node may show most benefit.
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FIGURE 7. While a bifocal right ventricular (RV) system should 
not be chosen as an initial treatment method, it may be an ac-
ceptable alternative in patients who have undergone unsuccess-
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